CSL Behring

From Wikipedia, the free encyclopedia
CSL Behring LLC
IndustryBiopharmaceutical, health care
HeadquartersKing of Prussia, Pennsylvania
Key people
Paul Perreault, CEO and Managing Director of CSL Limited
Number of employees
ParentCSL Limited

CSL Behring is a biopharmaceutical company, manufacturing plasma-derived, and recombination therapeutic products. Its line of therapies includes products for the treatment of bleeding disorders such as hemophilia); hereditary angioedema; inherited respiratory disease; and neurological disorders. The company's products are also used in cardiac surgery, organ transplantation, burn treatment, and to prevent hemolytic diseases in newborns.[2][3]

CSL Behring is a combination of Behringwerke, founded in 1904 in Marburg, Germany by Emil von Behring, and the Commonwealth Serum Laboratories (CSL), established in Australia in 1916 to provide vaccines to the people of Australia, as well as other companies acquired since 2004


CSL Behring's parent company, CSL Limited, is headquartered in Melbourne, Victoria, Australia. As part of a global alignment, the CSL Behring brand was established in 2007. Previously known as ZLB Behring, the company's history dates back to 1904 when Behringwerke was founded in Germany by Emil von Behring, winner of the first Nobel Prize in Medicine as the inventor of serum therapy or serology.[4]

CSL Behring operates CSL Plasma, one of the world's largest plasma collection networks. It has over 12,000 employees and more than 270 plasma collection centers covering China, the US, and Europe.[5][6][7]


In 1904, Von Behring founded the Behringwerke in Marburg, Germany, for experimental work on disease prevention and the manufacture of sera and vaccines. In 1913, Behringwerke expanded to produce a gas gangrene antiserum and a cholera vaccine.

In 1916, the Commonwealth Serum Laboratories (now CSL Ltd.) were established in Australia to provide vaccines to the people of Australia and New Zealand. In 1930, CSL released an antivenom for tiger snake bites. In 1944, CSL began producing penicillin for the military and Australia.

In 1954, Australian CSL officer Val Bazeley assisted Jonas Salk with the production of the experimental polio vaccine used in the first clinical trials in the US. Bazeley returned to Australia to set up production of the Salk vaccine at CSL.

In 1981, Behringwerke introduced Haemate, human plasma coagulation factor VIII/von Willebrand factor complex for the treatment of patients with hemophilia A.

In 1991, CSL Limited was incorporated in Australia. In 2004, CSL Limited completed the acquisition of Aventis Behring,[8] combining it with ZLB Bioplasma to create ZLB Behring (later CSL Behring).

In 2007, ZLB Behring became CSL Behring. In 2009, ZLB Plasma changed its name to CSL Plasma to align with its parent company and opened plasma testing laboratories in Knoxville, Tennessee. Also in 2009, the National Organization for Rare Disorders (NORD) recognized CSL Behring for developing and marketing a treatment in the U.S. for acute bleeding episodes in patients with congenital fibrinogen deficiency and the Swiss government awarded CSL Behring the Tell Award.

In 2012, the European Organisation for Rare Diseases recognized CSL Behring for developing and manufacturing therapies to treat rare and serious medical conditions with a 2012 EURORDIS Company Award.[9]

Over the past century, CSL Behring has acquired: Aventis Behring, U.S. plasma collector Nabi, which helped form the world's largest plasma collection network in CSL Plasma; Calimmune, a leader in gene-modification and cell-delivery technology;[10] and Vitaeris,[11] a biopharmaceutical company focused on the development of Clazakizumab as a potential treatment option for organ transplant recipients experiencing rejection.

In 2021 CSL Behring opened its 300th CSL Plasma processing/donation center in the United States.


  • Beriglobin P, human hepatitis A immunoglobulin, liquid 16% solution for intramuscular injection
  • Berirab P, human rabies immunoglobulin, liquid 16% solution for intramuscular injection
  • Carimune NF, Sandoglobulin, Sanglopor human normal immunoglobulin, freeze-dried formulations for intravenous administration
  • Cytogam, human cytomegalovirus immunoglobulin. Liquid immunoglobulin containing a standardized amount of antibody to cytomegalovirus.[12]
  • Hepatitis B Immunoglobulin P Behring, human hepatitis B immunoglobulin, liquid 16% solution for intramuscular injection
  • Hizentra, Human normal immunoglobulin. Liquid 20% immunoglobulin solution, ready-to-use for subcutaneous administration.[13]
  • Privigen, human polyvalent immunoglobulin, liquid 10% solution for intravenous injection.[13]
  • Rhophylac human anti-D immunoglobulin. Prefilled syringes of highly purified anti-Rhesus factor D IgG for intravenous administration and intramuscular injection.
  • Tetagam P, human tetanus immunoglobulin, liquid 16% solution for intramuscular injection
  • Varicellon P, human varicella immunoglobulin, liquid 16% solution for intramuscular injection
Coagulation/bleeding disorders
  • Zemaira, freeze-dried Human Alpha1-proteinase inhibitor (A1-PI)
Critical care
  • AlbuRx, Alburex, Human Albumin Behring, Albuminar, human albumin solution (5%, 20% or 25% human albumin solutions)
  • Berinert P, freeze-dried human C1-esterase inhibitor (C1-INH) concentrate
  • Beriplex P/N, Kcentra, freeze-dried human prothrombin complex concentrate
  • Haemocomplettan P, RiaSTAP, freeze-dried human fibrinogen (factor I) concentrate
  • Kybernin P, freeze-dried human antithrombin III concentrate
  • Streptase, freeze-dried streptokinase
Wound healing
  • Beriplast P Combi-Set, fibrin sealant kit, freeze-dried fibrin sealant for topical application
  • Fibrogammin P, freeze-dried human coagulation factor XIII concentrate
  • TachoComb, fibrin sealant fleece-type, fleece-type collagen preparations coated with fibrin glue components
  • Hemgenix, an adeno-associated virus vector-based gene therapy for the treatment of adults with Hemophilia B (congenital Factor IX deficiency) who currently use Factor IX prophylaxis therapy, or have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes.[16]

(Note: Product availability varies from country to country, depending on registration status.)[17][18]


The company's headquarter is in King of Prussia, Pennsylvania.[19] It has 27,000+ employees in 30 countries.[1] Major manufacturing centers are located in Bern, Switzerland;Marburg, Germany; Kankakee, Illinois; and Broadmeadows, Australia.[19]


  1. ^ a b De Vane, Natalie (October 29, 2020). "CSL Named as One of the World's Best Employers". www.cslbehring.com. CSL Behring. Archived from the original on 2020-11-28. Retrieved February 22, 2021. Forbes magazine has named global biotechnology leader CSL Limited … to its World's Best Employers 2020 list.
  2. ^ "Our Story". www.cslbehring.com. CSL Behring. 2021. Retrieved February 22, 2021.
  3. ^ "CSL Behring is leading the way on rare and serious diseases". www.cslbehring.com. CSL Behring. Retrieved February 22, 2021.
  4. ^ Nobel Prize in Physiology or Medicine 1901 - Emil von Behring – Biographical. Nobel Lectures, Physiology or Medicine 1901-1921. Elsevier Publishing Company, Amsterdam. 1967. p. 16. Retrieved February 22, 2021 – via The Nobel Foundation. … for his work on serum therapy, especially its application against diphtheria …{{cite book}}: CS1 maint: url-status (link)
  5. ^ "About CSL Plasma". www.cslplasma.com. CSL Plasma. Archived from the original on 2018-10-30. Retrieved February 22, 2021. … operates one of the world's largest and most sophisticated plasma collection networks, …
  6. ^ "CSL Behring: new approaches against Covid-19". Healthcare Mittelhessen. 2020-08-04. Retrieved 2022-03-27.
  7. ^ "CSL Behring Company Information". Drugs.com. Retrieved 2022-03-27.
  8. ^ "Aventis disposes of Behring unit with $925M sale to Australia's CSL -". www.thepharmaletter.com. The Pharma Letter. December 15, 2003. Archived from the original on 2021-09-23. Retrieved February 22, 2021. … Aventis says that it has agreed to sell its Aventis Behring blood products business to Australia's CSL …
  9. ^ "EURORDIS". www.eurordis.org. March 22, 2012. Retrieved January 20, 2020.
  10. ^ C. S. L. Behring (August 28, 2017). "CSL Behring to Acquire Biotech Company Calimmune and its Proprietary Stem Cell Gene Therapy Platform". CSL Behring. Archived from the original on 2017-08-29. Retrieved February 22, 2021 – via prnewswire.com. …CSL Behring announced today that it has agreed to acquire Calimmune, Inc., …
  11. ^ C. S. L. Behring (June 8, 2020). "CSL Behring to Acquire Biotech Company Vitaeris". Archived from the original on 2020-06-09. Retrieved February 22, 2021 – via prnewswire.com. … CSL Behring announced today that it has agreed to acquire Vitaeris Inc. …
  12. ^ "Cytogam". Cytogam. Retrieved 2023-02-28.
  13. ^ a b "CSL Behring | Immune Deficiency Foundation". primaryimmune.org. Retrieved 2022-03-27.
  14. ^ "von Willebrand disease (VWD) Treatment | HUMATE-P". www.humate-p.com. Retrieved 2023-02-28.
  15. ^ "Factor IX Therapy for Hemophilia B | IDELVION coagulation factor IX (recombinant), albumin fusion protein". www.idelvion.com. Retrieved 2023-02-28.
  16. ^ "FDA Approves First Gene Therapy to Treat Adults with Hemophilia B". www.fda.gov. Retrieved 2023-01-12.
  17. ^ "CSL Behring's Global Products List". www.cslbehring.com. CSL Behring. Archived from the original on 2018-04-04. Retrieved February 22, 2021.
  18. ^ "All medicines for CSL Behring UK Limited - (emc)". www.medicines.org.uk. Retrieved 2022-03-27.
  19. ^ a b "CSL Behring's Worldwide Locations". www.cslbehring.com. CSL Behring. 2021. Archived from the original on 2018-08-16. Retrieved February 22, 2021.

External links[edit]